Europe - OHE

We found for

Slovak Republic

Insight
September 2023

Around The World in HTAs: The Slovak Republic – Valuing the Future

Cancer_WellcomeCollection_landscape

Insight
January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Blog 4

Insight
October 2022

The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?

Insight
March 2021

Does Government Funding Increase Public Sector Development of New Medicines?

Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective

Read more

Health Policy and Regulation

Opportunities to Increase Efficiency in Healthcare

Read more

Insight
September 2018

MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

Read more

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

Read more

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Read more

Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure

Read more

Improving Efficiency and Resource Allocation in Future Cancer Care

Read more

Biosimilar Competition: Lessons from Europe and Prospects for the US

Read more

New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options

Read more

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?

Read more

Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society

Read more